Chuzhou City, China, Oct. 10, 2024 — JIN MEDICAL INTERNATIONAL LTD. (the “Company” or “JinMed”) (NASDAQ: ZJYL), an industry leader in Assistive Technologies (“AT”), and a manufacturer and developer of wheelchairs and living aids products, today announced the start of construction for JinMed’s new manufacturing facility in Chuzhou City, Anhui Province, China. JinMed (Anhui) Co., Ltd., a newly established subsidiary of JinMed, will operate the Chuzhou JinMed plant (the “New Facility”), which is designed to be an internationally standardized, innovative, and high-end wheelchair and electric wheelchair manufacturing factory. With advanced production lines in place, more innovative high-quality products are expected to solidify JinMed’s leadership in the AT industry.

JinMed’s Chairman and Chief Executive Officer, Mr. Wang Erqi, stated that the commencement of the New Facility represents another significant milestone for JinMed. JinMed will leverage the establishment of the New Facility as an opportunity to continue upholding the goal of “global technology for the benefit of mankind”, further strengthen its leadership in the AT industry, and demonstrate JinMed’s responsibility and commitment.

The new Chuzhou facility is anticipated to begin operations in 2025. In addition to expanding the capacity of JinMed’s current manual wheelchair lines, JinMed will also produce electric wheelchairs and electric scooter specialty lines. Healthcare products such as micro hyperbaric chambers and scientific cosmetic products will also be manufactured at the New Facility.

About Jin Medical International Ltd.

Founded in 2006 and headquartered in Changzhou, Jiangsu Province of China, JinMed, designs, develops, manufactures and markets wheelchairs and living aids products for individuals with disabilities, the elderly, and for rehabilitation applications. Currently, JinMed operates two manufacturing plants, totaling approximately 230,000 square feet, in Changzhou City and Taizhou City, Jiangsu Province, China. JinMed is establishing a new facility spanning 430,000 square feet in Chuzhou, Anhui Province, China. JinMed has over 40 distributors in China and over 20 international distributors. The majority of JinMed’s wheelchair products, with more than 30 models, are sold to distributors in Japan and China, including Nissin Medical Industries Co., Ltd, one of the largest medical device distributors in Japan. JinMed continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: .

Forward-Looking Statement

This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements encompass statements regarding plans, objectives, goals, strategies, future events or performances, and underlying assumptions, along with other statements that are not statements of historical facts. When the Company uses terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not solely relate to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ significantly from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact: